Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

127.7K
Overview
127.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

259
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
259
Hepatic Portal System01:21

Hepatic Portal System

5.5K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.5K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Self-Evaluation: Self-Enhancement and Self-Verification03:00

Self-Evaluation: Self-Enhancement and Self-Verification

5.7K
Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
5.7K
Bioavailability Enhancement: Drug Solubility Enhancement01:16

Bioavailability Enhancement: Drug Solubility Enhancement

226
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
226

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shaping cell therapy manufacturing with metabolic understanding and control.

Trends in biotechnology·2026
Same author

Ferritin nanoparticles displaying rift valley fever virus glycoprotein elicit potent dendritic cell activation in vitro.

Virology journal·2026
Same author

Bridging process diversity in cell therapies toward standardization of manufacturing workflows.

Cytotherapy·2026
Same author

3D co-cultures of primary human hepatocytes and Kupffer-like cells to address innate immune responses to rAAV.

Scientific reports·2025
Same author

Site-directed tyrosinase conjugation on engineered ferritin retains immune recognition.

Scientific reports·2025
Same author

Engineering a Perfusion Bioreactor System for hiPSC-Derived Progenitor Co-Culture Capturing Microglial Features in CNS Development.

Biotechnology and bioengineering·2025

Related Experiment Video

Updated: Jan 20, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Enhancing Hepatitis C virus pseudoparticles infectivity through p7NS2 cellular expression.

Hugo R Soares1, Marina Ferreira-Fernandes1, Ana I Almeida1

  • 1iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal.

Journal of Virological Methods
|August 15, 2019
PubMed
Summary
This summary is machine-generated.

Stable production of Hepatitis C virus-like particles (HCVpp) was established to improve antiviral drug discovery. Co-expression of p7NS2 open reading frame (ORF) enhanced HCVpp infectivity, aiding HCV entry assessment.

Keywords:
Hepatitis C virusNS2RimantadinedFLEXp7

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Related Experiment Videos

Last Updated: Jan 20, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Hepatitis C virus-like particles (HCVpp) are crucial for evaluating HCV cell entry and screening antiviral drugs and vaccines.
  • Transient production methods for HCVpp often lead to variability, hindering reliable assessments.

Purpose of the Study:

  • To establish a stable production system for HCVpp to reduce variability.
  • To investigate the impact of p7NS2 open reading frame (ORF) co-expression on HCVpp infectivity and entry mechanisms.

Main Methods:

  • Developed a stable cell line for consistent HCVpp production.
  • Assessed HCVpp performance by evaluating human serum influence and CD81 cellular expression.
  • Studied the effect of p7NS2 ORF co-expression on HCVpp infectivity and characterized the underlying mechanisms.

Main Results:

  • Stable HCVpp production was successfully established, reducing variability.
  • Co-expression of p7NS2 ORF significantly enhanced HCVpp infectivity.
  • Enhanced infectivity was not due to increased particle production or envelope density but suggested a role for the p7 ion channel in pH-dependent cell entry.

Conclusions:

  • A stable HCVpp production system with enhanced infectivity was established.
  • Overexpression of p7NS2 ORF improves HCVpp infectivity, likely via the p7 ion channel.
  • This enhanced system offers improved HCV entry assessment for antiviral drug discovery and vaccine development.